SCHEMBL29348121

SCHEMBL29348121

CN(C)c1nn(CC(=O)Nc2ccc(=O)n(C)n2)c(=O)c2ccc(Cl)cc12

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
TP53 P04637 4/20 0.40
RXFP1 Q9HBX9 1/20 0.40
AKR1B1 P15121 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 2/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 3/20 0.38
ALDH1A1 P00352 1/20 0.38
S1PR2 O95136 1/20 0.38
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
MAT2A P31153 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29348124 0.96 MEN1 (0.43) KMT2AMEN1TP53RXFP1AKR1B1
SCHEMBL29348116 0.88 NLRP3 (0.46) KMT2ATP53RXFP1SMN1; SMN2TSHR
SCHEMBL29348106 0.86 NLRP3 (0.47) KMT2ATP53AKR1B1SMN1; SMN2TSHR
SCHEMBL24077029 0.83 MEN1 (0.44) KMT2AMEN1TP53RXFP1AKR1B1
SCHEMBL29348127 0.82 NLRP3 (0.46) KMT2AMEN1TP53RXFP1AKR1B1
SCHEMBL29348083 0.80 S1PR2 (0.46) KMT2AMEN1AKR1B1SMN1; SMN2TSHR
SCHEMBL29348084 0.75 KMO (0.46) KMT2AMEN1AKR1B1S1PR2MAT2A
SCHEMBL29348120 0.75 NLRP3 (0.53) KMT2AMEN1TP53RXFP1AKR1B1
SCHEMBL29348074 0.74 GAA (0.51) KMT2AMEN1RXFP1SMN1; SMN2TSHR
SCHEMBL29348119 0.74 NLRP3 (0.52) KMT2AMEN1TP53RXFP1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239757-A1 PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239757-A1 PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS NLRP3, NLRP1, PYCARD KMT2A 1964/4885MEN1 2642/4885TP53 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.